{
    "nct_id": "NCT03098550",
    "official_title": "Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined With Daratumumab in Participants With Advanced or Metastatic Solid Tumors",
    "inclusion_criteria": "For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com\n\n* Patients with metastatic or advanced solid tumors\n* Women with histologically or cytologically confirmed triple negative breast carcinoma\n* Participants with histologically or cytologically confirmed pancreatic adenocarcinoma\n* Participants with histologically or cytologically confirmed Non Small Cell Lung Cancer (NSCLC)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active brain metastases or leptomeningeal metastases.\n* Any serious or uncontrolled medical disorder\n* Prior malignancy active within the previous 3 years\n\nOther protocol defined inclusion/exclusion criteria could apply",
    "miscellaneous_criteria": ""
}